Acurx Pharmaceuticals Inc

ACXP

4.820USD

-0.240-4.74%

Close 11/04, 16:00（ET）Quotes delayed by 15 min

Acurx Pharmaceuticals Inc's Score

Industry at a Glance

Industry Ranking

236 / 501

Overall Ranking

422 / 4682

Industry

Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 3 analysts

Buy

Current Rating

61.700

Target Price

+1119.37%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Acurx Pharmaceuticals Inc Highlights

StrengthsRisks

Acurx Pharmaceuticals, Inc. is a late-stage biopharmaceutical company focused on developing a new class of small molecule antibiotics for difficult-to-treat bacterial infections. It develops antibiotic candidates with a Gram-positive selective spectrum (GPSS) that block the active site of the Gram positive specific bacterial enzyme deoxyribonucleic acid (DNA) polymerase IIIC (pol IIIC), inhibiting DNA replication and leading to Gram-positive bacterial cell death. Its research and development (R&D) pipeline include antibiotic product candidates that target Gram-positive bacteria, including Clostridioides difficile (C. difficile), methicillin-resistant Staphylococcus aureus (MRSA), vancomycin resistant Enterococcus (VRE) and drug-resistant Streptococcus pneumoniae (DRSP). Its lead antibiotic candidate, ibezapolstat targets the pol IIIC enzyme. Phase II clinical data validate the efficacy of its lead antibiotic candidate, as well as pol IIIC as an appropriate bacterial target.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 0.00.

Overvalued

The company’s latest PE is -0.08, at a high 3-year percentile range.

Institutional Selling

The latest institutional holdings are 221.10K shares, decreasing 32.81% quarter-over-quarter.

Held by James Simons

Star Investor James Simons holds 4.39K shares of this stock.

Lower Market Activity

The company has less investor interest, with a 20-day turnover ratio of -0.88.

There is no financial score for this company; the Biotechnology & Medical Research industry's average is 6.92.

Score

Industry at a Glance

Previous score

0.00

Change

0



Financials



Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings



Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency



Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential



Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns



Key Metrics

Free cash flow

No Data

The company’s current valuation score is 6.27, which is lower than the Biotechnology & Medical Research industry's average of 6.98. Its current P/E ratio is -0.08, which is -95.53% below the recent high of -0.00 and -7098.82% above the recent low of -5.48.

Score

Industry at a Glance

Previous score

6.27

Change

0

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 236/501

No Data

The company’s current earnings forecast score is 8.00, which is lower than the Biotechnology & Medical Research industry's average of 8.04. The average price target for Acurx Pharmaceuticals Inc is 30.50, with a high of 165.80 and a low of 20.00.

Score

Industry at a Glance

Previous score

8.00

Change

0

Support & Resistance

No Data

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

The company’s current price momentum score is 8.96, which is higher than the Biotechnology & Medical Research industry's average of 6.80. Sideways: Currently, the stock price is trading between the resistance level at 8.60 and the support level at 4.33, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

8.95

Change

0.01

Support & Resistance

No Data

Institutional Confidence

Currency: USD Updated: 2025-10-27

The company’s current institutional recognition score is 3.00, which is lower than the Biotechnology & Medical Research industry's average of 5.11. The latest institutional shareholding proportion is 13.95%, representing a quarter-over-quarter decrease of 38.03%. The largest institutional shareholder is The Vanguard, holding a total of 7.28K shares, representing 0.46% of shares outstanding, with 85.23% decrease in holdings.

Score

Industry at a Glance

Previous score

3.00

Change

0

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Armistice Capital LLC

144.47K

-0.98%

Luci (David P)

57.38K

--

DeLuccia (Robert J)

50.70K

--

Prospect Financial Services LLC

14.84K

-19.04%

Shawah (Robert G)

9.46K

--

Geode Capital Management, L.L.C.

7.32K

-14.63%

The Vanguard Group, Inc.

Star Investors

7.28K

-72.51%

Sailer (Carl)

7.11K

--

Morgan Stanley Smith Barney LLC

5.31K

--

Renaissance Technologies LLC

Star Investors

4.39K

+230.00%



1

2



There is no risk assessment score for the company; the Biotechnology & Medical Research industry's average is 3.49. The company's beta value is -1.30. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.

Acurx Pharmaceuticals Inc

ACXP

4.63 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Ascendis Pharma A/S

ASND

8.60 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

CytomX Therapeutics Inc

CTMX

8.57 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Insmed Inc

INSM

8.47 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Amicus Therapeutics Inc

FOLD

8.46 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Krystal Biotech Inc

KRYS

8.36 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment